Recent achievements in the management of Raynaud's phenomenon

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 207-214

  Baumhäkel, Magnus ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Mechanisms; Raynaud's disease; Treatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; FLUOXETINE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOSARTAN; NIFEDIPINE; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAZOSIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; RHO KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SLX 2101; TADALAFIL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ASPHYXIA; BLOOD VESSEL FUNCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COLD STRESS; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; EMOTIONAL STRESS; FLUSHING; HEART PALPITATION; HUMAN; HYPOTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NAUSEA; NONHUMAN; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PHYSICAL STRESS; PREVALENCE; RAYNAUD PHENOMENON; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTEMIC SCLEROSIS; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VASOSPASM;

EID: 77950794725     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s5255     Document Type: Review

References (54)

1. Raynaud M. Local Asphyxia and Symmetrical Gangrene of the Extremities. London: New Sydenham Society. 1862.
2. Lewis T. Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart. 1929;15:7-101.
3. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10(5):485-488.
4. Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59(4): 633-653.
5. Kaheleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum. 1995;38:1-4.
6. Rajagopalan S, Pfenninger D, Kehrer C, et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum. 2003;48(7):1992-2000.
7. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 1999;221(4):312-325.
8. Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M. Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther. 2008;327(3):692-698.
9. Friedrich EB, Teo KK, Bohm M. ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol. 2006;95(2):61-67.
10. Kawaguchi Y, Takagi K, Hara M, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum. 2004;50(1):216-226.
11. Yardumian DA, Mackie IJ, Brennan EC, Bull H, Machin SJ. Platelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteers. Haemostasis. 1986;16(1):20-26.
12. Bertele V, Mussoni L, del Rosso G, et al. Defective fibrinolytic response in atherosclerotic patients - effect of iloprost and its possible mechanism of action. Thromb Haemost. 1988;60(2):141-144.
13. Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 2004;50(5):1578-1585.
14. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol. 2000;278(4):H1075-H1083.
15. Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res. 2004;94(10): 1367-1374.
16. Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol. 2005;289(1):H243-H250.
17. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet. 1990;336(8730):1530-1533.
18. Teh LS, Manning J, Moore T, Tully MP, O'Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol. 1995;34(7):636-641.
19. Franks AG Jr. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet. 1982;1(8263):76-77.
20. Kleckner M Jr, Allen EV, Wakim KG. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon; studies on blood flow and clinical manifestations. Circulation. 1951;3(5):681-689.
21. Stosic-Grujicic SD, Maksimovic DD, Stojkovic MB, Lukic ML. Pentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetes. Dev Immunol. 2001;8(3-4):213-221.
22. Kinney EL, Nicholas GG, Gallo J, Pontoriero C, Zelis R. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol. 1982;22(1):74-76.
23. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447-1457.
24. Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis. 2000;43(2):171-196.
25. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44(2):145-150.
26. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841-1847.
27. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol. 2001;19(5):503-508.
28. Stosic-Grujicic S, Maksimovic D, Badovinac V, et al. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. J Autoimmun. 2001;16(1):47-58.
29. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120(3):199-206.
30. Kawald A, Burmester GR, Huscher D, Sunderkotter C, Riemekasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol. 2008;35(9):1830-1837.
31. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Resp Crit Care Med. 2005;171(11):1292-1297.
32. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980-2985.
33. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum. 2003;48(1):282-283; author reply 3.
34. Kumana CR, Cheung GT, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis. 2004;63(11): 1522-1524.
35. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res. 2005;69(3):178-179.
36. Rosato E, Letizia C, Proietti M, et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. J Biol Regul Homeost Agents. 2009;23(1):23-29.
37. Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36(10):2264-2268.
38. Morelli S, Ferri C, Polettini E, et al. Plasma endothelin-1 levels, pulmonary hypertension and lung fibrosis in patients with systemic sclerosis. Am J Med. 1995;99(3):255-260.
39. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985-3993.
40. Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7):418-431.
41. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Treatment of Raynaud's phenomenon. Autoimmunity reviews. 2008;8(1): 62-68.
42. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006;40(11):1998-2002.
43. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42(12):2646-2655.
44. Pope J, Fenlon D, Thompson A, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2): CD000956.
45. Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 2004;50(12):3994-4001.
46. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129-1135.
47. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Exp Rev Cardiovasc Ther. 2005;3(3):441-451.
48. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105(13):1545-1547.
49. Bussemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J. Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis. 2009;207(2):567-572.
50. Chan CK, Mak JC, Man RY, Vanhoutte PM. Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta. J Pharmacol Exp Ther. 2009;329(2):820-826.
51. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008;35(9):1801-1808.
52. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40(9):1038-1043.
53. Pope J, Fenlon D, Thompson A, et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2): CD000954.
54. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford). 2005;44(5):587-596.